AMG 706 + panitumumab + gemcitabine + cisplatin

This is a four-drug combination regimen consisting of **AMG 706 (motesanib)**, **panitumumab**, **gemcitabine**, and **cisplatin**. - **AMG 706 (motesanib)** is an oral small-molecule multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (KIT). It primarily inhibits angiogenesis and tumor growth by blocking signaling pathways critical for tumor blood vessel formation and proliferation. - **Panitumumab** is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting cell growth and survival in EGFR-expressing tumors. - **Gemcitabine** is a nucleoside analog that interferes with DNA synthesis, resulting in apoptosis of rapidly dividing tumor cells. - **Cisplatin** is a platinum-containing DNA crosslinker, causing DNA damage and apoptosis in cancer cells. This combination was tested in a **Phase 1b clinical trial** to evaluate its safety and tolerability in patients with advanced cancer, particularly solid tumors[4].

Other names

motesanibpanitumumabgemcitabinecisplatin